UBS AM’s Foghorn Therapeutics FHTX Stock Holding History

UBS AM’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14K	Hold	2,876	–	–	﹤0.01%	3204
2026 Q1	$13.7K	Buy	2,876 +2,502	+669%	+$13.7K	﹤0.01%	3231
2025 Q4	$2.02K	Buy	+374	New	+$1.7K	﹤0.01%	3127

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UBS AM's FHTX Position: Q2 2026 in Review

UBS AM held its Foghorn Therapeutics (FHTX) position steady in Q2 2026 at 2,876 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #3204.

UBS AM first reported a position in FHTX in Q4 2025 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

UBS AM held 2,876 shares of Foghorn Therapeutics worth $14K as of Q2 2026.
UBS AM left its Foghorn Therapeutics share count unchanged in Q2 2026.
Foghorn Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3204 holding.
UBS AM first reported a position in Foghorn Therapeutics in Q4 2025 and has held it in 3 quarters since.
103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.